NYSEAMERICAN:VNRX VolitionRx (VNRX) Stock Price, News & Analysis $0.65 -0.02 (-2.38%) (As of 04:33 PM ET) Add Compare Share Share Today's Range$0.64▼$0.7150-Day Range N/A52-Week Range$0.43▼$1.38Volume119,905 shsAverage Volume173,291 shsMarket Capitalization$41.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesShort InterestStock AnalysisChartEarningsHeadlinesInsider TradesShort Interest Get VolitionRx alerts: Email Address Ad Monument Traders AllianceFREE TRAINING TODAY ➡️ How to profit from 2024 electionEarlier this year, Millionaire Trader Nate Bear of Monument Traders Alliance went live in front of thousands of traders and placed a unique trade that surged 1,129% in just 2 days... All using a unique trade that cost him less than $0.99 trade.Click here to RSVP to today's FREE training >>> About VolitionRx Stock (NYSEAMERICAN:VNRX)VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.Read More VNRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VNRX Stock News HeadlinesAugust 18, 2024 | gurufocus.comQ2 2024 VolitionRX Ltd Earnings Call TranscriptAugust 15, 2024 | markets.businessinsider.comVNRX Stock Earnings: VolitionRX Beats EPS, Misses Revenue for Q2 2024September 10, 2024 | Behind the Markets (Ad)The $15 Stock Powering NVIDIA, TESLA and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.May 12, 2024 | markets.businessinsider.comVolitionRX earnings preview: what Wall Street is expectingApril 23, 2024 | finance.yahoo.comNu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through AntechMarch 28, 2024 | seekingalpha.comVolitionRx Limited (VNRX) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comVolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | msn.comTELA Bio launches Liquifix surgical devices in the U.S.September 10, 2024 | Behind the Markets (Ad)The $15 Stock Powering NVIDIA, TESLA and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.March 20, 2024 | finance.yahoo.comVolition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in JapanFebruary 2, 2024 | finance.yahoo.comVolition to Share Nu.Q® NETs Strategy Update at Upcoming WebinarJanuary 6, 2024 | proactiveinvestors.comVolitionRx has 'compelling plans' to advance veterinary care in 2024January 4, 2024 | finance.yahoo.comVolition Issues Business Review 2023January 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF), Universal Health (UHS) and VolitionRX (VNRX)November 14, 2023 | finance.yahoo.comVolitionRx Limited Announces Third Quarter 2023 Financial Results and Business UpdateNovember 2, 2023 | finance.yahoo.comVNRX: Breakthrough Cancer Detection Method Disclosed at ESMO and in a Webinar - preliminary proof of concept work indicates simple blood test should be able to detect several types of cancer, potentially at Stages I & IINovember 1, 2023 | msn.comVolitionRX (VNRX) Price Target Increased by 7.93% to 3.76October 31, 2023 | msn.comEF Hutton Initiates Coverage of VolitionRX (VNRX) with Buy RecommendationSee More Headlines Receive VNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Diagnostics & Research Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:VNRX Previous SymbolNYSEMKT:VNRX CUSIPN/A CIKN/A Webwww.volitionrx.com Phone(646) 650-1351Fax65 32 8172 5651Employees80Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,270,000.00 Net Margins-9,158.31% Pretax Margin-9,257.43% Return on Equity-15,493.47% Return on Assets-149.54% Debt Debt-to-Equity RatioN/A Current Ratio0.69 Quick Ratio0.69 Sales & Book Value Annual Sales$310,000.00 Price / Sales136.12 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-13.36Miscellaneous Outstanding Shares63,180,000Free Float53,450,000Market Cap$42.20 million OptionableNot Optionable Beta1.59 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Martin Charles Faulkes Ph.D. (Age 80)Executive Chairman Comp: $239.51kMr. Cameron Reynolds MBA (Age 53)Founder, CEO, President & Director Comp: $572.43kDr. Gaetan Michel Ph.D. (Age 50)Chief Operating Officer Comp: $518.15kDr. Salvatore Thomas Butera DVM (Age 72)Chief Executive Officer of Volition Veterinary Diagnostics Development LLC Comp: $477.25kMr. Terig Hughes (Age 53)CFO & Treasurer Comp: $338.74kDr. Jacob Vincent Micallef MBA (Age 68)Ph.D., Chief Scientific Officer Comp: $571.55kMr. Nicholas Plummer (Age 53)Group General Counsel Ms. Louise Batchelor Day (Age 52)Group Chief Marketing & Communications Officer Mr. Thomas BygottSales & Marketing DirectorMr. Gael Forterre M.B.A. (Age 42)Chief Commercial Officer More ExecutivesKey CompetitorsRezoluteNASDAQ:RZLTDiaMedica TherapeuticsNASDAQ:DMACContext TherapeuticsNASDAQ:CNTXOptheaNASDAQ:OPTAtossa TherapeuticsNASDAQ:ATOSView All Competitors VNRX Stock Analysis - Frequently Asked Questions How were VolitionRx's earnings last quarter? VolitionRx Limited (NYSEAMERICAN:VNRX) announced its earnings results on Wednesday, August, 14th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The medical research company earned $0.40 million during the quarter, compared to analysts' expectations of $0.34 million. VolitionRx had a negative trailing twelve-month return on equity of 15,493.47% and a negative net margin of 9,158.31%. How do I buy shares of VolitionRx? Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of VolitionRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that VolitionRx investors own include Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and CRISPR Therapeutics (CRSP). This page (NYSEAMERICAN:VNRX) was last updated on 9/10/2024 by MarketBeat.com Staff From Our PartnersFREE TRAINING TODAY ➡️ How to profit from 2024 electionEarlier this year, Millionaire Trader Nate Bear of Monument Traders Alliance went live in front of thousands o...Monument Traders Alliance | SponsoredHow to grow a small trading account into a $100k? Why is Warren Buffett dumping stocks? Billionaires like Warren Buffett, Tim Cook, and Jeff Bezos are offloa...Timothy Sykes | SponsoredKamala’s Promise Will Kill America (Revealed)Kamala’s 3-Word Plan to Destroy America — Are You Prepared? Discover the secret plan that will bankrupt eve...Banyan Hill Publishing | SponsoredWarning For Nvidia HoldersHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart mi...Stansberry Research | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
